The EVAN Foundation is grateful for the support of the following partners

Neuroblastoma

What Is Neuroblastoma?

Neuroblastoma is one of the most complex and devastating of all pediatric cancers. It is a tumor of the sympathetic nervous system that quickly spreads throughout the entire body. It is a cowardly disease that primarily strikes young children before the age of 5. Neuroblastoma is extremely rare, with approximately 700 new cases a year seen in the U.S. Less that 30% of children diagnosed with high-risk disease survive.

Those fortunate enough to survive face a lifetime of treatment-related physical and emotional challenges, including the likelihood of developing a secondary malignancy. Only one hurdle stands between the unacceptable status quo and better treatments and a cure for this awful disease -- support for research.

A Few Facts To Consider...

  • The National Cancer Institute allocates $200 million out of its annual $5.1 billion budget to pediatric cancer research. That is just 4%, despite the fact that pediatric cancer is the number one disease killer of children in the U.S.

  • There is virtually no private pharmaceutical investment in neuroblastoma research due to a lack of market incentives.

  • The American Cancer Society dedicates less that 1% of its $1 billion in annual public revenues to pediatric cancer research. No figure is publicly available for neuroblastoma.